Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-1365 in Advanced Solid Tumors
NCT03134638Phase 1Terminated
- Sponsor
- Syros Pharmaceuticals
- Start
- May 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of mevociclib in solid tumor, ovarian cancer and breast cancer (6 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: First-cycle dose-limiting toxicities, ECG QTc Interval and 1 more. Started May 2017; status: terminated.
02
Drugs
mevociclib
03
Conditions
solid tumorovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT03134638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03134638.